Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

Singh AA, Schuurman K, Nevedomskaya E, Stelloo S, Linder S, Droog M, Kim Y, Sanders J, van der Poel H, Bergman AM, Wessels LF, Zwart W.

Life Sci Alliance. 2018 Dec 28;2(1):e201800115. doi: 10.26508/lsa.201800115. eCollection 2019 Feb.

2.

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

Schrijver W, Schuurman K, van Rossum A, Droog M, Jeronimo C, Salta S, Henrique R, Wesseling J, Moelans C, Linn SC, van den Heuvel M, van Diest P, Zwart W.

Mol Oncol. 2018 Nov;12(11):1884-1894. doi: 10.1002/1878-0261.12353. Epub 2018 Oct 12.

3.

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LF, Zwart W.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1316-E1325. doi: 10.1073/pnas.1615233114. Epub 2017 Feb 6. Erratum in: Proc Natl Acad Sci U S A. 2018 Jan 22;:. Mourits, Marian [corrected to Mourits, Marian J].

4.

The Estrogen Receptor α-Cistrome Beyond Breast Cancer.

Droog M, Mensink M, Zwart W.

Mol Endocrinol. 2016 Oct;30(10):1046-1058. Epub 2016 Aug 4. Review.

5.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.

Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6. Erratum in: Cancer Res. 2018 May 1;78(9):2446.

6.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.

Oncotarget. 2016 Jun 7;7(23):33901-18. doi: 10.18632/oncotarget.8983.

7.

SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.

Zwart W, Flach KD, Rudraraju B, Abdel-Fatah TM, Gojis O, Canisius S, Moore D, Nevedomskaya E, Opdam M, Droog M, Hofland I, Chan S, Shaw J, Ellis IO, Coombes RC, Carroll JS, Ali S, Palmieri C.

Clin Cancer Res. 2016 Jan 15;22(2):479-91. doi: 10.1158/1078-0432.CCR-14-3277. Epub 2015 Sep 14.

8.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22.

PMID:
25141981
9.

Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer.

Jansen MP, Knijnenburg T, Reijm EA, Simon I, Kerkhoven R, Droog M, Velds A, van Laere S, Dirix L, Alexi X, Foekens JA, Wessels L, Linn SC, Berns EM, Zwart W.

Cancer Res. 2013 Nov 15;73(22):6632-41. doi: 10.1158/0008-5472.CAN-13-0704.

10.

Tamoxifen resistance: from bench to bedside.

Droog M, Beelen K, Linn S, Zwart W.

Eur J Pharmacol. 2013 Oct 5;717(1-3):47-57. doi: 10.1016/j.ejphar.2012.11.071. Epub 2013 Mar 29. Review.

PMID:
23545365
11.

Self-regulated alternative splicing at the AHNAK locus.

de Morrée A, Droog M, Grand Moursel L, Bisschop IJ, Impagliazzo A, Frants RR, Klooster R, van der Maarel SM.

FASEB J. 2012 Jan;26(1):93-103. doi: 10.1096/fj.11-187971. Epub 2011 Sep 22.

PMID:
21940993

Supplemental Content

Support Center